April 27, 2018 09:40 AM EDT
R&D

Eye­ing block­buster mi­graine mar­ket, Al­ler­gan un­loads sec­ond set of pos­i­tive PhI­II re­sults for ubro­gepant

Brittany Meiling

Al­ler­gan $AGN rolled out its sec­ond wave of pos­i­tive Phase III da­ta for its oral mi­graine drug ubro­gepant, which nailed its end­points in the high­er …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times